ISA Moving HPV Vaccine into Phase II with $10.5M Round
By Cormac Sheridan
Tuesday, January 8, 2013
ISA Pharmaceuticals BV raised €8 million (US$10.5 million) in an internal financing round to fund a Phase II trial of its therapeutic vaccine for cervical cancer, ISA-HPV.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.